Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 10Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Uterine Cervical Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Pheochromocytoma 2Paraganglioma 2Ovarian Neoplasms 2Multiple Myeloma 2Mouth Neoplasms 2Melanoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Solid Tumor 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Neuroendocrine Tumor × Fluorodeoxyglucose F18 × 90 days × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡